San Francisco startup Structure Therapeutics can also be working on an oral, as soon as-every day GLP-1 drug known as GSBR-1290—the drug surpassed Wall Street’s anticipations in June every time a mid-phase examine showed average weight loss of around six% and it strategies to get started on A further mid-phase trial towards the tip of this yr�